Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $2.51 USD
Change Today -0.0601 / -2.34%
Volume 455.0
VBIV On Other Exchanges
As of 8:10 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

vbi vaccines inc (VBIV) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/5/14 - $3.98
52 Week Low
10/14/14 - $1.90
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for VBI VACCINES INC (VBIV)

Related News

No related news articles were found.

vbi vaccines inc (VBIV) Related Businessweek News

No Related Businessweek News Found

vbi vaccines inc (VBIV) Details

VBI Vaccines Inc. operates as a biopharmaceutical company in the United States. It develops eVLP vaccine platform that allows for the design of enveloped (“e”) virus-like particle vaccines that closely mimic the target virus. The company’s lead eVLP asset is a prophylactic Cytomegalovirus (CMV) vaccine. It is also developing a thermostable technology platform that enables the development of vaccines and biologics that can withstand storage or shipment at constantly fluctuating temperatures. The company was formerly known as Paulson Capital (Delaware) Corp and changed its name to VBI Vaccines Inc. in July 2014. VBI Vaccines Inc. is headquartered in Cambridge, Massachusetts.

18 Employees
Last Reported Date: 03/20/15

vbi vaccines inc (VBIV) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $548.8K
Chief Financial Officer
Total Annual Compensation: $313.7K
Senior Vice President of Research
Total Annual Compensation: $334.1K
Vice President of Formulations
Total Annual Compensation: $286.0K
Compensation as of Fiscal Year 2014.

vbi vaccines inc (VBIV) Key Developments

VBI Vaccines Inc Presents at BIO International Convention 2015, Jun-17-2015 11:30 AM

VBI Vaccines Inc Presents at BIO International Convention 2015, Jun-17-2015 11:30 AM. Venue: Pennsylvania Convention Center, Philadelphia, Pennsylvania, United States. Speakers: David Evander Anderson, Senior Vice President of Research.

VBI Vaccines Inc, Annual General Meeting, May 12, 2015

VBI Vaccines Inc, Annual General Meeting, May 12, 2015., at 13:00 Eastern Daylight. Location: Hotel Marlowe, 25 Edwin H Land Blvd. Agenda: To elect seven directors to serve terms of one year each; to approve, on an advisory basis, the frequency of holding an advisory vote on executive compensation; to approve, on an advisory basis, the compensation of named executive officers; to ratify the appointment of Peterson Sullivan LLP as independent registered public accounting firm for the fiscal year ending December 31, 2015; and to transact such other business as may properly come before the annual meeting or any adjournments thereof.

VBI Vaccines, Inc. Announces New Data Supporting the Manufacture of Prophylactic CMV Vaccine Candidate

VBI Vaccines Inc. provided an update on the progress of its cytomegalovirus vaccine development program on April 8, 2015 at the World Vaccine Congress 2015 in Washington, D.C. Dr. David E. Anderson, company's Senior Vice President of Research, presented new data from interim yield and purity testing of VBI-1501A, company's prophylactic CMV vaccine candidate, which is now being manufactured in quantities needed for planned toxicology, stability, and clinical studies. The company's eVLP vaccine platform allows for the design of enveloped virus-like particle vaccines. eVLPs are a new class of vaccines that are designed to resemble the structure of viruses, but do not contain any potentially infectious viral material. Because of their structural similarity to viruses found in nature, eVLPs are capable of imparting greater immunity than immunization with the same recombinant target protein alone. During recent testing, the company employed electron microscopy to confirm the integrity of the eVLP particles (drug substance) used to create VBI-1501A. A separate in vivo potency assay assessed the consistency and potency of multiple batches of VBI-1501A, with positive interim results. Purity measurements are expected to meet regulatory requirements for clinical evaluation of the vaccine candidate. The company plans to initiate formal toxicology studies in the second quarter of 2015.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VBIV:US $2.51 USD -0.0601

VBIV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VBIV.
View Industry Companies

Industry Analysis


Industry Average

Valuation VBIV Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 200.2x
Price/Book 8.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 158.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VBI VACCINES INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at